Gastrointestinal stromal tumors: Current management

Research output: Contribution to journalReview articlepeer-review

38 Scopus citations

Abstract

Herein, we review the current management of localized and advanced gastrointestinal stromal tumors (GISTs). Although surgery remains the standard of care for patients with localized GIST, adjuvant imatinib can delay recurrence in some of these patients. In patients with advanced or metastatic disease, the standard of care is imatinib and surgery of residual masses is an option. Preoperative imatinib is an emerging treatment option for patients who require cytoreductive therapy. Sunitinib is a standard second-line therapy.

Original languageEnglish (US)
Pages (from-to)530-538
Number of pages9
JournalJournal of surgical oncology
Volume102
Issue number5
DOIs
StatePublished - Oct 1 2010

Keywords

  • Adjuvant
  • GIST
  • Gastrointestinal stromal tumors
  • Imatinib
  • Neoadjuvant
  • Sunitinib

ASJC Scopus subject areas

  • Surgery
  • Oncology

Fingerprint

Dive into the research topics of 'Gastrointestinal stromal tumors: Current management'. Together they form a unique fingerprint.

Cite this